Forte Biosciences Inc., a clinical-stage biopharmaceutical company specializing in autoimmune and autoimmune-related diseases, has announced positive results from its Phase 1b trial for FB102 in the treatment of celiac disease. The study, which involved 32 subjects, demonstrated a significant improvement for those treated with FB102 compared to the placebo group. The trial reported a 73% improvement in the Vh:Cd ratio and a 42% reduction in gluten challenge-induced gastrointestinal symptoms for FB102-treated subjects. No dropouts or severe adverse events were reported. Forte Biosciences is set to initiate a Phase 2 celiac disease trial, with a topline readout expected in 2026. The results from the Phase 1b study were discussed in a conference call hosted by Forte Biosciences, featuring Prof. Jason Tye-Din, the principal investigator of the study.